- Home
- KALU vs RCKT Comparison
KALU vs RCKT Comparison
Compare KALU & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- RCKT
- Stock Information
- Founded
- KALU 1946
- RCKT 1999
- Country
- KALU United States
- RCKT United States
- Employees
- KALU N/A
- RCKT N/A
- Industry
- KALU Metal Fabrications
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- KALU Industrials
- RCKT Health Care
- Exchange
- KALU Nasdaq
- RCKT Nasdaq
- Market Cap
- KALU 1.3B
- RCKT 1.4B
- IPO Year
- KALU 1991
- RCKT N/A
- Fundamental
- Price
- KALU $81.65
- RCKT $14.11
- Analyst Decision
- KALU Buy
- RCKT Strong Buy
- Analyst Count
- KALU 3
- RCKT 10
- Target Price
- KALU $82.33
- RCKT $52.40
- AVG Volume (30 Days)
- KALU 159.7K
- RCKT 947.0K
- Earning Date
- KALU 10-23-2024
- RCKT 11-07-2024
- Dividend Yield
- KALU 3.77%
- RCKT N/A
- EPS Growth
- KALU 252.66
- RCKT N/A
- EPS
- KALU 2.90
- RCKT N/A
- Revenue
- KALU $2,980,300,000.00
- RCKT N/A
- Revenue This Year
- KALU N/A
- RCKT N/A
- Revenue Next Year
- KALU $6.84
- RCKT $411.05
- P/E Ratio
- KALU $28.13
- RCKT N/A
- Revenue Growth
- KALU N/A
- RCKT N/A
- 52 Week Low
- KALU $57.52
- RCKT $12.62
- 52 Week High
- KALU $102.42
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- KALU 59.69
- RCKT 37.41
- Support Level
- KALU $79.07
- RCKT $12.62
- Resistance Level
- KALU $84.44
- RCKT $17.83
- Average True Range (ATR)
- KALU 2.31
- RCKT 1.03
- MACD
- KALU -0.30
- RCKT -0.28
- Stochastic Oscillator
- KALU 52.46
- RCKT 26.85
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.